REMEGEN(688331) Shang Hai Zheng Quan Bao·2025-05-22 20:27Core Viewpoint - The company plans to issue 19 million new H-shares to enhance its capital strength and support business expansion, with a focus on research and development in the biopharmaceutical sector [2][13][14]. Group 1: Share Placement Details - The company has entered into a placement agreement on May 22, 2025, to issue 19,000,000 new H-shares, representing approximately 10.02% of the existing H-shares and 3.49% of the total issued shares as of the announcement date [2][12]. - The placement price is set at HKD 42.44 per share, which reflects a discount of approximately 9.51% compared to the last trading day's closing price of HKD 46.90 [5][6]. - The net proceeds from the placement are expected to be around HKD 796 million after deducting commissions and estimated expenses [6][14]. Group 2: Use of Proceeds - The funds raised from the share placement will be utilized to enhance the company's research and development capabilities and support business expansion plans, particularly for its core product, RC18, in treating conditions such as myasthenia gravis and membranous nephropathy [14]. Group 3: Corporate Governance and Compliance - The share placement is authorized under the general mandate granted at the annual general meeting, allowing the board to issue up to 108,866,416 shares without further shareholder approval [12]. - The company will apply for the listing and trading approval of the new shares on the Hong Kong Stock Exchange [17]. - The company will comply with the regulations of the China Securities Regulatory Commission and complete the necessary filing procedures [18].